Cardiovascular Diseases: From Basic Research to Clinical Application—4th Edition

A Special Issue of Life (ISSN 2075-1729) belonging to the section "Medical Research".

Deadline for manuscript submissions: 28 February 2027 | Viewed by 751

Editors

Special Issue Information

Dear Colleagues,

We are grateful to the researchers who contributed to the previous three volumes of this issue. Readers can find the papers published in the previous three volumes following the links provided below.

https://www.mdpi.com/journal/life/special_issues/0UO87783VR
https://www.mdpi.com/journal/life/special_issues/CVD
https://www.mdpi.com/journal/life/special_issues/VI3MSHVX3B

Furthermore, we are pleased to announce the upcoming publication of our Special Issue, entitled “Cardiovascular Diseases: From Basic Research to Clinical Application—4th Edition”.

Presently, cardiovascular disease (CVD) is the most prominent threat to human health. Because CVD is still the leading cause of death, research in this field is of critical importance. Although recent decades have seen tremendous progress regarding the study of risk factors of CVD, the molecular basis of atherosclerosis, coronary revascularization, and treatment of heart failure (these being only a few areas of research interest), much remains to be done, and the prospects are promising. In order to improve the quality and length of life for those at risk for CVD, research aimed at identifying better predictors of this disease and better means for prevention and treatment must be prioritized.

The purpose of this Special Issue is to identify several important advances in clinical and basic research in CVD that will provide the tools for further progress in the prevention and treatment of this disease. As artificial intelligence plays an increasingly important role in the prevention of CVD, it is also worth considering this aspect.

Therefore, it is our pleasure to cordially invite those of you with an interest in CVD research and willing to be part of this Special Issue to publish papers that address novelties in both clinical and basic cardiovascular research. We encourage the submission of all types of manuscripts, including original studies, reviews, and short communications.

Dr. Cristiana Bustea
Prof. Dr. Delia Mirela Tit
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • CVDs
  • risk factors
  • prevention
  • treatment
  • novelties in research
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 960 KB  
Review
Aldosterone Synthase Inhibitors: Emerging Therapeutic Strategies in Resistant Hypertension
by Akshyaya Pradhan, Monika Bhandari, Abhishek Singh, Pravesh Vishwakarma, Kunal Mahajan, Marco Alfonso Perrone and Akash Batta
Life 2026, 16(9), 1495; https://doi.org/10.3390/life16091495 - 7 Sep 2026
Viewed by 420
Abstract
Resistant hypertension (RH) is a high-risk phenotype associated with increased cardiovascular and renal morbidity despite multidrug therapy. Dysregulation of the renin–angiotensin–aldosterone system (RAAS), particularly excess aldosterone activity, plays a central role in the pathophysiology of RH. Although conventional RAAS-targeted therapies including angiotensin-converting enzyme [...] Read more.
Resistant hypertension (RH) is a high-risk phenotype associated with increased cardiovascular and renal morbidity despite multidrug therapy. Dysregulation of the renin–angiotensin–aldosterone system (RAAS), particularly excess aldosterone activity, plays a central role in the pathophysiology of RH. Although conventional RAAS-targeted therapies including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists improve outcomes, their effectiveness is limited by aldosterone breakthrough, persistent non-genomic aldosterone effects, hyperkalaemia, and off-target adverse effects. Aldosterone synthase inhibitors (ASIs) have emerged as a novel therapeutic strategy targeting CYP11B2, the terminal enzyme responsible for aldosterone biosynthesis. This review summarises the physiological basis of aldosterone synthesis, the pathological consequences of aldosterone excess, and the pharmacological evolution of ASIs. Early-generation agents were limited by inadequate selectivity between CYP11B2 and the closely related CYP11B1 enzyme, resulting in cortisol suppression and deoxycorticosterone accumulation. Advances in structural biology and medicinal chemistry enabled the development of second-generation ASIs with markedly improved selectivity and preserved cortisol biosynthesis. Recent clinical trials of baxdrostat, lorundrostat, vicadrostat, and dexfadrostat have demonstrated clinically meaningful reductions in blood pressure and albuminuria with acceptable safety profiles. Based on the positive trial data, baxdrostat has become the first in class ASI to be approved by regulatory authorities for management of uncontrolled hypertension. Full article
►▼ Show Figures

Figure 1

Back to TopTop